Benefits
May help reduce alcohol consumption in heavy drinkers
Oral puerarin has been studied as an adjunct in heavy drinkers, with pilot data showing reduced beer consumption in laboratory drinking sessions compared with placebo, supporting interest as a non-aversive option for those seeking to moderate their alcohol intake.
Supports healthy cardiovascular function
Puerarin has been characterized as a vasodilatory isoflavone with antioxidant activity at the endothelium, providing a rationale for traditional and modern use in supporting healthy blood vessel tone and cardiovascular comfort during physical activity.
Provides neuroprotective antioxidant support
Preclinical research describes puerarin crossing the blood–brain barrier and reducing oxidative stress and excitotoxic damage in models of cerebral ischemia, helping support brain resilience under low-oxygen and high-stress conditions in laboratory models.
May support healthy glucose handling
Animal studies suggest puerarin influences insulin signaling and glucose uptake, contributing to interest in kudzu-derived isoflavones as adjuncts within broader healthy lifestyle strategies for maintaining normal blood sugar metabolism.
Mechanism of action
Endothelial nitric oxide and vasodilation
Puerarin enhances endothelial nitric oxide synthesis and reduces vascular oxidative stress, producing vasodilation in preclinical vascular preparations and providing pharmacologic basis for cardiovascular effects observed with kudzu-derived isoflavones.
Modulation of cerebral autophagy and apoptosis
In rodent models of transient cerebral ischemia, puerarin attenuates autophagy at the ischemic penumbra in neurons but not in astrocytes, and suppresses apoptotic signaling pathways, supporting neuroprotection in stroke-relevant injury models.
ALDH2 and dopaminergic modulation
Kudzu isoflavones, including daidzin paired with puerarin, modulate mitochondrial aldehyde dehydrogenase 2 and mesolimbic dopaminergic signaling associated with alcohol reward, offering mechanistic context for the observed reduction in alcohol consumption.
Antioxidant and anti-inflammatory signaling
Puerarin scavenges reactive oxygen species, modulates Nrf2-related antioxidant gene programs, and downregulates NF-κB-driven inflammatory mediators in preclinical models, contributing to a broad cardiovascular and neuroprotective pharmacology.
Clinical trials
Double-blind, placebo-controlled, crossover pilot study of oral puerarin 1,200 mg/day for one week followed by an afternoon drinking session (Penetar et al., Drug and Alcohol Dependence).
10 healthy adult heavy drinkers.
Average beer consumption was lower on puerarin (about 2.4 beers) than on placebo (about 3.5 beers). No participant drank five or six beers on puerarin, versus several on placebo. First demonstration that a single kudzu isoflavone alters human drinking behavior, supporting interest as an adjunct for moderating alcohol intake.
Randomized, double-blind, placebo-controlled trial of a standardized kudzu isoflavone extract (NPI-031) in naturalistic drinking sessions (Lukas et al., Alcohol Clin Exp Res).
14 heavy drinkers studied as their own controls.
Kudzu extract (rich in puerarin) significantly reduced beer consumption, sip number, and sip volume during 90-minute ad libitum drinking sessions, without subjective intoxication differences or adverse events. Supports the role of kudzu isoflavones, including puerarin, in reducing voluntary alcohol intake in heavy drinkers.
Comprehensive review of puerarin pharmacology across cardiovascular, cerebrovascular, diabetic, and neurodegenerative indications (Zhou, Zhang, Peng, Phytotherapy Research).
Aggregated preclinical and clinical literature.
Review synthesizes evidence for vasodilatory, cardioprotective, neuroprotective, antioxidant, and antiinflammatory effects of puerarin and notes that injectable formulations in Chinese cardiovascular practice are more strongly supported than oral supplement use, helping calibrate expectations for oral puerarin products.